Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast‐enhanced MR imaging of the central nervous system

Publisher: John Wiley & Sons Inc

E-ISSN: 1522-2586|41|3|788-796

ISSN: 1053-1807

Source: JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol.41, Iss.3, 2015-03, pp. : 788-796

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content